Table 1.
Baseline characteristics and follow-up in patients infected with SARS-CoV-2 and non-infected with SARS-CoV-2.
| Non-Infected SARS-CoV-2 (n = 130) |
Infected SARS-CoV-2 (n = 44) |
p Value | |
|---|---|---|---|
| Sex, M/F, n (%) | 93 (71)/37 (29) | 27 (61)/17 (39) | 0.207 |
| Age, (yr) | 65.1 ± 9.9 | 64.3 ± 10.3 | 0.648 |
| Liver disease etiology, n (%) | |||
| Alcohol | 59 (45) | 16 (36) | |
| Virus (HBV/HCV) | 26 (20) | 9 (21) | |
| Alcohol + Virus | 12 (9) | 8 (18) | 0.241 |
| MASLD | 15 (12) | 2 (4) | |
| Others | 18 (14) | 9 (21) | |
| Previous decompensation, ** n (%) | 73 (56) | 26 (59) | 0.734 |
| Active alcohol intake, n (%) | 18 (14) | 15 (34) | 0.003 |
| Diabetes mellitus, n (%) | 46 (35) | 18 (41) | 0.511 |
| Arterial hypertension, n (%) | 51 (39) | 21 (48) | 0.323 |
| Dyslipidemia, n (%) | 29 (22) | 14 (32) | 0.206 |
| Body mass index (BMI), (kg/m2) | 27.1 ± 4.3 | 29 ± 5.6 | 0.017 |
| Obesity, n (%) | 30 (23) | 19 (43) | 0.010 |
| Active smoking, n (%) | 40 (31) | 9 (20) | 0.189 |
| Child-Pugh score, (points) | 5.7 ± 1.1 | 6.1 ± 1.2 | 0.060 |
| MELD score, (points) | 8.6 ± 2.6 | 8.8 ± 3.1 | 0.804 |
| Bilirubin, (µmol/L) | 22.9 ± 14.9 | 26.5 ± 17.5 | 0.199 |
| Creatinine, (µmol/L) | 78.5 ± 19.8 | 79.8 ± 24.8 | 0.708 |
| Prothrombin time, (INR) | 1.14 ± 0.2 | 1.22 ± 0.3 | 0.049 |
| Albumin, (g/L) | 38.6 ± 5.2 | 36.6 ± 6.2 | 0.029 |
| Platelet count, ×10−3 | 131 ± 74 | 109 ± 62 | 0.073 |
| Hemoglobin, (g/L) | 135 ± 22 | 125 ± 21 | 0.010 |
| Aspartate aminotransferase, (U/L) | 36 ± 23 | 40 ± 22 | 0.459 |
| Alanine aminotransferase, (U/L) | 29 ± 20 | 39 ± 22 | 0.357 |
| Gamma glutamyltranspeptidase, (U/L) | 157 ± 331 | 129 ± 142 | 0.595 |
| Alkaline phosphatase, (U/L) | 119 ± 59 | 122 ± 60 | 0.783 |
| Liver stiffness, (kPa) | 23.9 ± 20.1 | 20.1 ± 14.6 | 0.410 |
| Esophageal varices small/large, n (%) | 30 (23)/62 (48) | 13 (29)/23 (5) | 0.706 |
| Death during follow-up (FU), n (%) | 5 (4) | 14 (32) | 0.001 |
| Decompensation during FU/after SARS-CoV-2 infection, n (%) | 10 (8) | 16 (36) | 0.001 |
Categorical variables (%) were compared using the Fisher exact test. Continuous variables (mean values ± SD), were compared using the unpaired Student’s test or the non-parametric Mann–Whitney rank-sum test. ** Patients with previous clinical ascites, at least one previous episode of encephalopathy ≥ grade II of West Haven, or variceal bleeding. BMI: body mass index; FU: follow-up; HBV: hepatitis B virus; HCV: hepatitis C virus; INR: International normalized ratio; MASLD: metabolic dysfunction-associated steatotic liver disease; MELD: model for end-stage liver disease, kPa: kilopascal.